Stocks Health care CASIF

OTC · Health care

CASI Pharmaceuticals, Inc. (CASIF)

CASI Pharmaceuticals, Inc. reported revenue of $20.7M in fiscal 2025, down 27.4% from a year earlier. It posted a net loss of $48.1M. In fiscal 2025 capital spending exceeded operating cash flow by $20.8M. At December 31, 2025 it held $5.6M in cash against $19.2M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.

Watch CASIF in 60 seconds

Follow CASIF

Free, no password. An email when CASIF files with the SEC.

Key facts about CASI Pharmaceuticals, Inc.

Net worth

CASI Pharmaceuticals, Inc. reported shareholders' equity (book value: assets minus liabilities) of -$37.3M at December 31, 2025. We hold no current market value for it.

Revenue and profit

In fiscal 2025 revenue was $20.7M (-27.4% year on year), with a net loss of $48.1M.

Cash flow

In fiscal 2025 operations used $20.8M of cash.

Latest report

The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on May 15, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What CASI Pharmaceuticals, Inc. does

CASI Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CASIF.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where CASIF ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What CASI Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 2, 2026
   Foreign issuer update 6-K
2. August 14, 2026
   Foreign issuer update 6-K
3. August 13, 2026
   Foreign issuer update 6-K
4. July 15, 2026
   Foreign issuer update 6-K
5. June 29, 2026
   Foreign issuer update 6-K
6. June 23, 2026
   Delisting notice 25-NSE
7. June 2, 2026
   Foreign issuer update 6-K
8. May 18, 2026
   Activist stake changed SCHEDULE 13D/A
9. May 15, 2026
   Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue fell 27% to $20.7M versus the prior year; diluted EPS -$2.59 versus -$2.56.
10. April 21, 2026
    Form NT 20-F filing NT 20-F

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 23, 2026. Insider transactions on SEC

Insider trades

What the people running CASI Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CASIF

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Foresite Capital Fund VI LP 0% (February 13, 2026); Zhou Quan 4.8% (January 20, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CASIF

What does CASI Pharmaceuticals, Inc. do?

CASI Pharmaceuticals, Inc. is a company in the Health care sector, listed on OTC as CASIF. Its shares trade on OTC under the ticker CASIF.

What is CASI Pharmaceuticals, Inc.'s net worth?

CASI Pharmaceuticals, Inc. reported shareholders' equity (book value: assets minus liabilities) of -$37.3M at December 31, 2025. We hold no current market value for it.

Is CASI Pharmaceuticals, Inc. profitable?

No. In fiscal 2025 it reported a net loss of $48.1M on revenue of $20.7M.

How much revenue does CASI Pharmaceuticals, Inc. make?

In fiscal 2025 CASI Pharmaceuticals, Inc. reported revenue of $20.7M. That is 27.4% less than a year earlier.

When did CASI Pharmaceuticals, Inc. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 2, 2026.

Similar companies

Compare CASIF with

Compare CASIF with any company

Follow CASIF

Get an email when CASI Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CASIF

Free, no password. An email when CASIF files with the SEC.

Where the numbers come from

Financial figures are the values CASI Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.